Axim® Biotechnologies granted a “patent” for suppository formulations comprising of cannabinoids
AXIM® Biotechnologies, Inc., a world leader in cannabinoid research and product development, announced that the United States Patent and Trademark Office (USPTO) has issued the company a new Notice of Allowance for a patent (Application No. 16/122,079) on a suppository composition comprising cannabinoids.
Congress directs the FDA to “sample current CBD products for mislabeling & doctoring”
Congress through the 2020 federal spending bill directs the FDA to “sample current CBD products for mislabeling & doctoring”. This along with 4 other Marijuana, Hemp & CBD stipulations was added.
Koi CBD is hit with a class-action lawsuit.
Koi CBD, LLC has been hit with a class action in which 2 customers claim that the California company’s products are illegal given their “prominent systematic” mislabeling for purposes unapproved by the FDA.
The EPA has approved 10 pesticides for 2020 hemp season
The Environmental Protection Agency (EPA) on Thursday, December 19th, approved the use of 10 pesticides to manage insect pests and diseases. 9 are biopesticides and 1 is a conventional pesticide.
Do you have a CBD Recall Plan?
A CBD business faces both immediate and incidental costs when faced with a product recall. It is easy to calculate immediate costs such as salaries for staff to redirect resources into the management of a recall plan or the cost of advertisements to notify the public of your CBD product recall.